The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study
Open accessAbstract
Purpose: Secondary and therapy-related acute myeloid leukemia (sAML and tAML, respectively) remain therapeutic challenges. Still, it is unclear whether their inferior outcome compared with de novo acute myeloid leukemia (AML) varies as a result of previous hematologic disease or can be explained by differences in karyotype and/or age. Patients and Methods: In a Danish national population-based study of 3,055 unselected patients with AML diagnosed from 2000 to 2013, we compared the frequencies and characteristics of tAML, myelodysplastic syndrome (MDS) -sAML, and non-MDS-sAML (chronic myelomonocytic leukemia and myeloproliferative neoplasia) versus de novo AML. Limited to intensive therapy patients, we compared chance of complete remission by logistic regression analysis and used a pseudo-value approach to compare relative risk (RR) of death at 90 days, 1 year, and 3 years, overall and stratified by age and karyotype. Results were given crude and adjusted with 95% CIs. Results: Overall, frequencies of sAML and tAML were 19.8% and 6.6%, respectively. sAML, but not tAML, was associated with low likelihood of receiving intensive treatment. Among intensive therapy patients (n = 1,567), antecedent myeloid disorder or prior cytotoxic exposure was associated with decreased complete remission rates and inferior survival (3-year adjusted RR for MDS-sAML, non-MDS-sAML, and tAML: RR, 1.14; 95% CI, 1.02 to 1.32; RR, 1.27; 95% CI, 1.16 to 1.34; and RR, 1.16; 95% CI, 1.03 to 1.32, respectively) compared with de novo AML. Among patients ≥ 60 years old and patients with adverse karyotype, previous MDS or tAML did not impact overall outcomes, whereas non-MDS-sAML was associated with inferior survival across age and cytogenetic risk groups (adverse risk cytogenetics: 1-year adjusted RR, 1.47; 95% CI, 1.23 to 1.76; patients ≥ 60 years old: 1-year adjusted RR, 1.31; 95% CI, 1.06 to 1.61). Conclusion: Our results support that de novo AML, sAML, and tAML are biologically and prognostically distinct subtypes of AML. Patients with non-MDS-sAML have dismal outcomes, independent of age and cytogenetics. Previous myeloid disorder, age, and cytogenetics are crucial determinants of outcomes and should be integrated in treatment recommendations for these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
WHO classification of haematolymphoid tumours
Gaillard, F., Weerakkody, Y., & Sharma, R. (2010) · Radiopaedia.org · doi:10.53347/rid-9250 · Cited by 3,776
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
The Danish National Hospital Register. A valuable source of data for modern health sciences.
Andersen, T. F., Madsen, M., Jørgensen, J. O. L., Mellemkjoer, L., & Olsen, J. H. (1999) · PubMed · Cited by 2,026
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,946
Grimwade, D., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., Burnett, A. K., & on behalf of the National Cancer Research Institute Adult Leukaemia Working Group (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,938
Thygesen, S. K., Christiansen, C. F., Christensen, S., Lash, T. L., & Sørensen, H. T. (2011) · BMC Medical Research Methodology · doi:10.1186/1471-2288-11-83 · Cited by 1,195
Paschka, P., Schlenk, R. F., Gaidzik, V. I., Habdank, M., Krönke, J., Bullinger, L., Späth, D., Kayser, S., Zucknick, M., Götze, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3762 · Cited by 801
The Danish Cancer Registry--history, content, quality and use.
Storm, H. H., Michelsen, E. V., Clemmensen, I. H., & Pihl, J. (1997) · PubMed · Cited by 790
Clonal Architecture of Secondary Acute Myeloid Leukemia
Walter, M. J., Shen, D., Ding, L., Shao, J., Koboldt, D. C., Chen, K., Larson, D. E., McLellan, M. D., Dooling, D., Abbott, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106968 · Cited by 775
Greenland, S. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh221 · Cited by 727
Smith, S. M., Le Beau, M. M., Huo, D., Karrison, T., Sobecks, R. M., Anastasi, J., Vardiman, J. W., Rowley, J. D., & Larson, R. A. (2003) · Blood · doi:10.1182/blood-2002-11-3343 · Cited by 682
Kayser, S., Döhner, K., Krauter, J., Köhne, C.-H., Horst, H. A., Held, G., von Lilienfeld-Toal, M., Wilhelm, S., Kündgen, A., Götze, K., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301713 · Cited by 487
Taskesen, E., Bullinger, L., Corbacioglu, A., Sanders, M. A., Erpelinck, C. A. J., Wouters, B. J., van der Poel-van de Luytgaarde, S. C., Damm, F., Krauter, J., Ganser, A., et al. (2011) · Blood · doi:10.1182/blood-2010-09-307280 · Cited by 384
Analyzing survival curves at a fixed point in time
Klein, J. P., Logan, B., Harhoff, M., & Andersen, P. K. (2007) · Statistics in Medicine · doi:10.1002/sim.2864 · Cited by 315
Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1405 · Cited by 308
Self-citationSchoch, C., Kern, W., Schnittger, S., Hiddemann, W., & Haferlach, T. (2004) · Leukemia · doi:10.1038/sj.leu.2403187 · Cited by 284
Metzeler, K. H., Becker, H., Maharry, K., Radmacher, M. D., Kohlschmidt, J., Mrózek, K., Nicolet, D., Whitman, S. P., Wu, Y.-Z., Schwind, S., et al. (2011) · Blood · doi:10.1182/blood-2011-08-368225 · Cited by 275
Hulegårdh, E., Nilsson, C., Lazarevic, V., Garelius, H., Antunovic, P., Rangert Derolf, Å., Möllgård, L., Uggla, B., Wennström, L., Wahlin, A., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.23908 · Cited by 269
Mauritzson, N., Albin, M., Rylander, L., Billström, R., Ahlgren, T., Mikoczy, Z., Björk, J., Strömberg, U., Nilsson, P., Mitelman, F., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402713 · Cited by 269
Mendler, J. H., Maharry, K., Radmacher, M. D., Mrózek, K., Becker, H., Metzeler, K. H., Schwind, S., Whitman, S. P., Khalife, J., Kohlschmidt, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.6652 · Cited by 268
Morton, L. M., Dores, G. M., Tucker, M. A., Kim, C. J., Onel, K., Gilbert, E. S., Fraumeni, J. F., & Curtis, R. E. (2013) · Blood · doi:10.1182/blood-2012-08-448068 · Cited by 233
Genetics of therapy-related myelodysplasia and acute myeloid leukemia
Pedersen-Bjergaard, J., Andersen, M. K., Andersen, M. T., & Christiansen, D. H. (2008) · Leukemia · doi:10.1038/sj.leu.2405078 · Cited by 232
Self-citationRegression Analysis of Restricted Mean Survival Time Based on Pseudo-Observations
Andersen, P. K., Hansen, M. G., & Klein, J. P. (2004) · Lifetime Data Analysis · doi:10.1007/s10985-004-4771-0 · Cited by 219
Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia
Litzow, M. R., Tarima, S., Pérez, W. S., Bolwell, B. J., Cairo, M. S., Camitta, B. M., Cutler, C. S., de Lima, M., DiPersio, J. F., Gale, R. P., et al. (2010) · Blood · doi:10.1182/blood-2009-10-249128 · Cited by 213
Bacher, U., Haferlach, T., Kern, W., Haferlach, C., & Schnittger, S. (2007) · Haematologica · doi:10.3324/haematol.10869 · Cited by 164
Regression Analysis of Censored Data Using Pseudo-observations
Parner, E. T., & Andersen, P. K. (2010) · The Stata Journal Promoting communications on statistics and Stata · doi:10.1177/1536867x1001000308 · Cited by 134
Miesner, M., Haferlach, C., Bacher, U., Weiss, T., Macijewski, K., Kohlmann, A., Klein, H., Dugas, M., Kern, W., Schnittger, S., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279794 · Cited by 129
Etiology and Management of Therapy-Related Myeloid Leukemia
Larson, R. A. (2007) · Hematology · doi:10.1182/asheducation-2007.1.453 · Cited by 95
Østgård, L. S. G., Nørgaard, J. M., Sengeløv, H., Severinsen, M. T., Friis, L. S., Marcher, C. W., Dufva, I. H., & Nørgaard, M. (2014) · Leukemia · doi:10.1038/leu.2014.234 · Cited by 81
Self-citationBochtler, T., Stölzel, F., Heilig, C. E., Kunz, C., Mohr, B., Jauch, A. S., Janssen, J. W. G., Krämer, M., Benner, A., Bornhäuser, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.7921 · Cited by 76
Underreporting of Myeloid Malignancies by United States Cancer Registries
Craig, B. M., Rollison, D. E. M., List, A. F., & Cogle, C. R. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-1087 · Cited by 76
Data quality in the Danish National Acute Leukemia Registry: a hematological data resource
Østgård, L. S. G., Nørgaard, M., Nørgaard, J. M., Severinsen, M. T., Sengeløv, H., Friis, L. S., Jensen, M. K., & Nielsen, O. J. (2013) · Clinical Epidemiology · doi:10.2147/clep.s48411 · Cited by 68
Self-citationCytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia
Medeiros, B. C., Othus, M. K. D., Fang, M., Appelbaum, F. R., & Erba, H. P. (2014) · Haematologica · doi:10.3324/haematol.2014.117267 · Cited by 30
Self-citationAcquired copy number alterations of miRNA genes in acute myeloid leukemia are uncommon
Ramsingh, G., Jacoby, M. A., Shao, J., de Jesus, R., Shen, D., Trissal, M. C., Getz, A. H., Ley, T. J., Walter, M. J., & Link, D. C. (2013) · Blood · doi:10.1182/blood-2013-03-488007 · Cited by 16
The Role Of Early TP53 Mutations On The Evolution Of Therapy-Related AML
Wong, T. N., Ramsingh, G., Young, A. L., Shen, D., Miller, C., Lamprecht, T. L., Heath, S. E., Fulton, R. S., Mardis, E. R., Ding, L., et al. (2013) · Blood · doi:10.1182/blood.v122.21.5.5 · Cited by 12
Cited by
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D., Solomon, S. R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6112 · Cited by 1,025
Self-citationEpidemiology of acute myeloid leukemia: Recent progress and enduring challenges
Shallis, R. M., Wang, R., Davidoff, A., Ma, X., & Zeidan, A. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.04.005 · Cited by 941
Short, N. J., Rytting, M. E., & Cortes, J. E. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31041-9 · Cited by 781
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
O'Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., Arber, D. A., Bhatt, V., Bixby, D., Blum, W., Coutre, S. E., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0116 · Cited by 654
Metadata
- Authors
- Granfeldt Østgård, L. S., Medeiros, B. C., Sengeløv, H., Nørgaard, M., Andersen, M. K., Dufva, I. H., Friis, L. S., Kjeldsen, E., Marcher, C. W., Preiss, B., Severinsen, M., & Nørgaard, J. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-11-01
- Volume
- 33
- Issue
- 31
- Pages
- 3641-3649
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2111724321
- Cited by
- 451
- References
- 37
- FWCI
- 17.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.